| Drug Name |
Naltrexone |
| Drug ID |
BADD_D01527 |
| Description |
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. |
| Indications and Usage |
Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program. |
| Marketing Status |
approved; investigational; vet_approved |
| ATC Code |
N07BB04 |
| DrugBank ID |
DB00704
|
| KEGG ID |
D05113
|
| MeSH ID |
D009271
|
| PubChem ID |
5360515
|
| TTD Drug ID |
D0PG8O
|
| NDC Product Code |
16447-0689; 69641-0002; 82105-003; 0406-3940; 65757-300; 0406-4605; 43798-006; 65757-360; 65757-301 |
| UNII |
5S6W795CQM
|
| Synonyms |
Naltrexone | Antaxone | Trexan | EN-1639A | EN 1639A | EN1639A | ReVia | Nemexin | Nalorex | Naltrexone Hydrochloride | Celupan |
